Lifco AB has acquired a majority stake in Rhein83 Srl
July 2018 — Lifco AB has acquired a majority stake in the Italian dental company Rhein83 Srl. Financial details have not been disclosed.
Lifco acquires and develops market-leading niche operations with the potential to deliver sustainable profit growth and strong cash flows. The group is listed on Nasdaq Stockholm and has three business areas: dental, demolition & tools and systems solutions. The company has a clear corporate philosophy which implies a long-term perspective, focus on profits and a highly decentralized organization. As of today, the investment group controls circa140 companies in 30 countries, generating revenues of over US$1 billion.
Established in 1983 and located in Bologna, Italy, Rhein83 has innovated the dental market with the introduction of elastic spherical attachments (previously were only metallic) for dental implants. The company's technology is highly recognized and appreciated worldwide.
Our role in the transaction
Oaklins' team in Italy advised the buyer in this transaction.
Ingvar Ljungqvist
Head of Acquisitions, Lifco AB
Talk to the deal team
Related deals
UKAT Group has acquired Bayberry Limited
UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.
Learn moreMedicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
Learn moreQuimpharma has completed the divestiture of a product portfolio to Megalabs
Quimpharma has completed the divestiture of a product portfolio to Megalabs México.
Learn more